Near‐infrared light‐responsive Nitric oxide microcarrier for multimodal tumor therapy

Abstract

Nitric oxide (NO) has shown great potential in tumor therapy, and the development of a platform for precise and controllable NO release still needs to be explored. Herein, a microfluidic electrospray strategy is proposed for the fabrication of hydrogel microspheres encapsulating NO donors (S‐nitrosoglutathione, GSNO) together with black phosphorus (BP) and chemotherapeutic doxorubicin (DOX) as microcarriers for tumor therapy. Based on the excellent photothermal property of BP and thermal sensitivity of GSNO, the microcarriers exhibit a near‐infrared light (NIR)‐responsive NO release behavior. Besides, the photothermal performance of the microcarriers accelerates the release of DOX. All these contribute to the excellent tumor‐killing effect of the microcarriers by combining multiple therapeutic strategies including NO therapy, photothermal therapy, and chemotherapy. Moreover, it was demonstrated that the NIR‐responsive NO delivery microcarriers could significantly inhibit tumor growth without apparent side effects in vivo. Therefore, it is believed that the novel NIR‐responsive NO microcarriers are promising candidates in clinical tumor therapy applications.

A CO-mediated photothermal therapy to kill drug-resistant bacteria and minimize thermal injury for infected diabetic wound healing

“…16,17 For example, NO- and H 2 S-mediated PTT can exhibit an enhanced synergetic efficiency on bacterial inhibition (over temperatures ranging from 50 °C to 55 °C) and can promote immunomodulatory cell migration as well as angiogenesis for infected wound healing. 18–22 Despite numerous studies on H 2 S- and NO-mediated PTT, CO-mediated PTT is rarely reported for wound healing, 23 and neither its therapeutic effect nor mechanism has been explored for use in infected diabetic wound healing yet.…”